ArticlePloS one2015
Osteoprotegerin Induces Apoptosis of Osteoclasts and Osteoclast Precursor Cells via the Fas/Fas Ligand Pathway.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Correlation between osteoprotegerin and coronary artery calcification in diabetic subjects: a systematic review of observational studies.BMC cardiovascular disorders · 2023Pooled it
- In silico exploration of osteoclast precursor inhibition for preventing rapid bone loss after denosumab discontinuation.NPJ systems biology and applications · 2026Article
- In vitro anti-inflammatory potential and in vivo anti-arthritis activities of Ximenia caffra extract on antigen-induced arthritis in rats.Scientific reports · 2026Article
- Metal complexes containing vitamin B6-based scaffold as potential DNA/BSA-binding agents inducing apoptosis in hepatocarcinoma (HepG2) cells.Molecular diversity · 2025Article
- Article
- Biomaterial Cues for Regulation of Osteoclast Differentiation and Function in Bone Regeneration.Advanced therapeutics · 2025Article
- The PANoptosis-related hippocampal molecular subtypes and key biomarkers in Alzheimer's disease patients.Scientific reports · 2024Article
- New Horizons: Translational Aspects of Osteomorphs.The Journal of clinical endocrinology and metabolism · 2024Review
- p-Smad3 differentially regulates the cytological behavior of osteoclasts before and after osteoblasts maturation.Molecular biology reports · 2024Article
- Expression of osteogenic factors in FasL-deficient calvarial cells.Physiological research · 2023Article
- The Mechanism of Osteoprotegerin-Induced Osteoclast Pyroptosis In Vitro.International journal of molecular sciences · 2023Article
- Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation.Current osteoporosis reports · 2022Review
- Upregulation of osteoprotegerin inhibitsExperimental and therapeutic medicine · 2022Article
- Bone Alterations in Inflammatory Bowel Diseases: Role of Osteoprotegerin.Journal of clinical medicine · 2022Article
- Determination of Therapeutic and Safety Effects ofBioMed research international · 2022Article
- New Insights Into Osteoclast Biology.JBMR plus · 2021Review
- Effects of the TNFRSF11B Mutation Associated With Calcium Pyrophosphate Deposition Disease in Osteoclastogenesis in a Murine Model.Arthritis & rheumatology (Hoboken, N.J.) · 2021Article
- Advances in mesenchymal stem cell transplantation for the treatment of osteoporosis.Cell proliferation · 2021Review
- 4-Acetylantroquinonol B Inhibits Osteoclastogenesis by Inhibiting the Autophagy Pathway in a Simulated Microgravity Model.International journal of molecular sciences · 2020Article
- Positive and negative regulators of osteoclast apoptosis.Bone reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoprotegerin (OPG) is known to inhibit differentiation and activation of osteoclasts (OCs) by functioning as a decoy receptor blocking interactions between RANK and RANKL. However, the exact role of OPG in the survival/apoptosis of OCs remains unclear. OPG caused increased rates of apoptosis of both OCs and osteoclast precursor cells (OPCs). The expression of Fas and activated caspase-8 was increased by both 20 ng/mL and 40 ng/mL of OPG, but was markedly decreased at 80 ng/mL. Interestingly, we noted that while levels of Fas ligand (FasL) increased with increasing doses of OPG, the soluble form of FasL in the supernatant decreased. The results of a co-immunoprecipitation assay suggested that the decrease of sFasL might be caused by the binding of OPG. This would block the inhibition of the apoptosis of OCs and OPCs. Furthermore, changes in expression levels of Bax/Bcl-2, cleaved-caspase-9, cleaved-caspased-3 and the translocation of cytochrome c, illustrated that OPG induced apoptosis of OCs and OPCs via the classic Fas/FasL apoptosis pathway, and was mediated by mitochondria. Altogether, our results demonstrate that OPG induces OCs and OPCs apoptosis partly by the Fas/FasL signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.